Medicare weight loss drug pilot on ice as insurers decline to contribute
The Centers for Medicare & Medicaid Services (CMS) has hit pause on its pilot programme designed to offer insurer-fronted access …
Post
-
-
Immunotherapy in locally advanced HNSCC: is there still room for new agents?
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly. In June 2025, …
-
MSD-backed Ray locks in $125m to back eye drug pipeline
Ray Therapeutics has secured $125m in a Series B funding round, as the gene therapy-focused biopharma eyes a breakout on …
-
FDA approves MSD’s once-daily HIV combo Idvynso
MSD (Merck & Co) has secured a US approval for its two-drug human immunodeficiency virus (HIV) combination therapy, Idvynso (doravirine/islatravir), …
-
BioAegis and Prenosis partner for inflammatory disease therapies
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. The collaboration will evaluate …
-
BioAegis and Prenosis partner for inflammatory disease therapies
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases. The collaboration will evaluate …
-
The definitive infrastructure for modern drug development
Paradigm Health delivers a unified, AI-powered clinical research platform embedded within a national network of community and academic sites. By …
-
Health Canada approves Biocon’s two denosumab biosimilars
Biocon has received a Notice of Compliance from Health Canada for Bosaya (denosumab) and Vevzuo (denosumab), both biosimilars referencing Prolia …
-
Eli Lilly doubles down on in vivo with $7bn Kelonia buyout
Eli Lilly has agreed to acquire Massachusetts-based gene therapy developer, Kelonia Therapeutics, for up to $7bn – marking the pharma’s …
-
Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy
Pfizer and Astellas have received the US Food and Drug Administration (FDA) acceptance for priority review of their supplemental biologics …
-
Asahi Kasei acquires German company Aicuris
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company. The move comes after Asahi Kasei signed …
-
British patients risking “fake” weight loss drugs, despite safety concerns, survey says
A survey by digital healthcare provider Zava has revealed that British patients are increasingly turning to potentially unregulated weight loss …
-
Boehringer Ingelheim launches AI centre in London
Boehringer Ingelheim has launched a new artificial intelligence (AI) and machine learning (ML) centre in London, representing the company’s latest …
-
Beyond GLP-1Rs: emerging targets poised to gain share of obesity market
Glucagon-like peptide-1 receptor (GLP-1R) therapeutics are not the only contributors to the rapidly growing global obesity market. The non-GLP-1R landscape, …
-
Trump backs psychedelics for mental health in new executive order
US President Donald Trump has signed an executive order focused on accelerating the route of psychedelics to the market, adding …
